Global Custom Market Research Reports Provider Company

phone

Veloxis Pharmaceuticals AS (VELO) - Financial and Strategic SWOT Analysis Review

  • Published Date: 05 Jul 2018
  • Number of Pages: 45
  • Category: SWOT Analysis
  • Country: Denmark
Veloxis Pharmaceuticals AS (VELO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the companys key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description A detailed description of the companys operations and business divisions.
- Corporate strategy Analysts summarization of the companys business strategy.
- SWOT Analysis A detailed analysis of the companys strengths, weakness, opportunities and threats.
- Company history Progression of key events associated with the company.
- Major products and services A list of major products, services and brands of the company.
- Key competitors A list of key competitors to the company.
- Key employees A list of the key executives of the company.
- Executive biographies A brief summary of the executives employment history.
- Key operational heads A list of personnel heading key departments/functions.
- Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Veloxis Pharmaceuticals A/S (Veloxis) is a specialty pharmaceutical company that identifies, develops and commercializes pharmaceutical drugs in transplantation and adjacent therapies. The company developed ENVARSUS XR (tacrolimus extended-release tablets) for the prophylaxis of organ rejection in kidney transplant patients. ENVARSUS is developed based on the companys proprietary, patented drug delivery technology, MeltDose, which is designed to enhance the absorption and bioavailability of select orally administered drugs. Veloxis out licensed the commercial rights of Envarsus MENA region, Canada and China. The company sells ENVARSUS XR to wholesalers, specialty pharmacies and other customers. Veloxis is headquartered in Copenhagen, Denmark.

Veloxis Pharmaceuticals AS Key Recent Developments

May 14,2018: Veloxis Pharmaceuticals Announces Financial Results for the First Three Months of 2018
Apr 13,2018: Veloxis Pharmaceuticals - Passing of Annual General Meeting 2018
Apr 03,2018: Veloxis Appoints Morten Marott as Chief Financial Officer
Feb 27,2018: Veloxis Pharmaceuticals Releases Annual Report for 2017
Feb 14,2018: Veloxis Secures $60M in Debt Financing

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The companys core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company
Publisher Name : GlobalData


List of Tables 5
List of Figures 5
Section 1 - About the Company 6
Veloxis Pharmaceuticals A/S - Key Facts 6
Veloxis Pharmaceuticals A/S - Key Employees 7
Veloxis Pharmaceuticals A/S - Key Employee Biographies 8
Veloxis Pharmaceuticals A/S - Major Products and Services 9
Veloxis Pharmaceuticals A/S - History 10
Veloxis Pharmaceuticals A/S - Company Statement 12
Veloxis Pharmaceuticals A/S - Locations And Subsidiaries 13
Head Office 13
Other Locations & Subsidiaries 13
Section 2 Company Analysis 14
Company Overview 14
Veloxis Pharmaceuticals A/S - Business Description 15
Veloxis Pharmaceuticals A/S - Corporate Strategy 16
Veloxis Pharmaceuticals A/S - SWOT Analysis 17
SWOT Analysis - Overview 17
Veloxis Pharmaceuticals A/S - Strengths 17
Veloxis Pharmaceuticals A/S - Weaknesses 18
Veloxis Pharmaceuticals A/S - Opportunities 19
Veloxis Pharmaceuticals A/S - Threats 20
Veloxis Pharmaceuticals A/S - Key Competitors 21
Section 3 Company Financial Ratios 22
Financial Ratios - Capital Market Ratios 22
Financial Ratios - Annual Ratios 23
Performance Chart 25
Financial Performance 25
Financial Ratios - Interim Ratios 26
Financial Ratios - Ratio Charts 27
Section 4 Companys Lifesciences Financial Deals and Alliances 28
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 28
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 29
Veloxis Pharmaceuticals A/S, Recent Deals Summary 30
Section 5 Companys Recent Developments 31
May 14, 2018: Veloxis Pharmaceuticals Announces Financial Results for the First Three Months of 2018 31
Apr 13, 2018: Veloxis Pharmaceuticals - Passing of Annual General Meeting 2018 32
Apr 03, 2018: Veloxis Appoints Morten Marott as Chief Financial Officer 33
Feb 27, 2018: Veloxis Pharmaceuticals Releases Annual Report for 2017 34
Feb 14, 2018: Veloxis Secures $60M in Debt Financing 35
Nov 14, 2017: Veloxis Pharmaceuticals Announces Financial Results for the First Nine Months of 2017 36
Sep 20, 2017: Alastair McEwan Steps Down as Chief Operating Officer of Veloxis Pharmaceuticals 37
Sep 13, 2017: Veloxis Pharmaceuticals Appoints Ulf Meier-Kriesche, MD, as Chief Scientific Officer 38
Aug 16, 2017: Veloxis Pharmaceuticals Announces Financial Results for the First Six Months of 2017 39
May 16, 2017: Veloxis Pharmaceuticals Announces Financial Results for the First Three Months of 2017 40
Section 6 Appendix 41
Methodology 41
Ratio Definitions 41
About GlobalData 45
Contact Us 45
Disclaimer 45

List Of Tables

List of Tables
Veloxis Pharmaceuticals A/S, Key Facts 6
Veloxis Pharmaceuticals A/S, Key Employees 7
Veloxis Pharmaceuticals A/S, Key Employee Biographies 8
Veloxis Pharmaceuticals A/S, Major Products and Services 9
Veloxis Pharmaceuticals A/S, History 10
Veloxis Pharmaceuticals A/S, Subsidiaries 13
Veloxis Pharmaceuticals A/S, Key Competitors 21
Veloxis Pharmaceuticals A/S, Ratios based on current share price 22
Veloxis Pharmaceuticals A/S, Annual Ratios 23
Veloxis Pharmaceuticals A/S, Annual Ratios (Cont...1) 24
Veloxis Pharmaceuticals A/S, Interim Ratios 26
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 28
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 29
Veloxis Pharmaceuticals A/S, Recent Deals Summary 30
Currency Codes 41
Capital Market Ratios 41
Equity Ratios 42
Profitability Ratios 42
Cost Ratios 43
Liquidity Ratios 43
Leverage Ratios 44
Efficiency Ratios 44

List Of Figures

List of Figures
Veloxis Pharmaceuticals A/S, Performance Chart (2013 - 2017) 25
Veloxis Pharmaceuticals A/S, Ratio Charts 27
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 28
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 29

Veloxis Pharmaceuticals AS (VELO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by

View Report

Veloxis Pharmaceuticals A/S (Veloxis) is a specialty pharmaceutical company that identifies, develops and commercializes pharmaceutical drugs in transplantation and adjacent therapies. The company developed ENVARSUS XR (tacrolimus extended-release tablets) for

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports